The U.S. pet nutraceuticals market was valued at USD 2.45 billion in 2026. This market is expected to reach USD 4.15 billion by 2036, growing at a CAGR of 5.5% from 2026 to 2036.

U.S. Pet Nutraceuticals Market - Key Highlights

• California is the largest market for pet nutraceuticals in the U.S., driven by massive e-commerce penetration, a highly affluent consumer base, and a strong cultural emphasis on sustainable, natural health products.
• Dogs constitute the largest pet type segment, holding around 75-80% share of supplement sales due to higher average healthcare expenditures and the prevalence of large-breed mobility issues.
• The feline segment is experiencing rapid growth, fueled by the fact that kitten-owning households are now approaching parity with puppy-owning households across the country.
• Chewables and Soft Chews dominate the product form category, capturing nearly half the market due to their massive success in ensuring daily administration compliance by mimicking high-value treats.
• Proteins and Peptides, mainly collagen-based joint supplements, represent the largest product category by revenue, heavily driven by the aging dog population.
• Probiotics and Prebiotics are the fastest-growing product segment, driven by increasing veterinary endorsement and massive consumer awareness regarding the critical importance of gut health.
• Preventive Care & General Wellness account for the largest application segment, reflecting the massive consumer shift toward proactive, lifelong health management rather than reactive disease treatment.
• Specialty Pet Retail and Veterinary Clinics remain highly significant distribution channels, offering crucial professional endorsement and specialized product knowledge.
• Online Channels is the fastest-growing distribution network, expanding at a double-digit CAGR as consumers increasingly favor the convenience of automated subscription deliveries.
• The market features intense competition between global conglomerates like Purina and Mars, established U.S. specialists like Nutramax Laboratories, and agile, digital-native brands such as Zesty Paws and Native Pet.
• Technological breakthroughs, such as the achievement of cost parity for algae-derived omega-3s, are actively mitigating supply chain vulnerabilities and appealing to eco-conscious American consumers.

U.S. Pet Nutraceuticals Market Overview

The large scale of the U.S. nutraceuticals market is directly anchored by the huge pet population in the country. According to recent industry surveys, an estimated 66% of American households, representing 86.9 million families, own at least one pet, with industry projections reaching up to 95 million households. The demographic makeup is heavily skewed toward dogs, which reside in over half of all pet-owning households (65.1 million dog-owning households), followed by a rapidly growing population of indoor cats. As these animals are increasingly viewed as equal family members, American pet owners demonstrate a willingness to invest discretionary income into premium health interventions. Recent data indicates that over 85% of these consumers believe that functional nutrition and targeted supplementation are absolutely essential for their pets' overall well-being.

A key factor driving the overall growth of the pet nutraceuticals market in the U.S. is the rapidly aging demographic of the American pet population. Advances in baseline nutrition and veterinary care have significantly extended the lifespans of U.S. dogs and cats. Consequently, the prevalence of age-related conditions, mainly osteoarthritis, cognitive decline, and chronic renal issues, has surged. Senior pets, generally classified as those over seven years of age (10+ for large breed dogs), now constitute a highly significant portion of the total companion animal population. This demographic reality sustains massive, continuous demand for joint health formulations featuring glucosamine, chondroitin, and collagen peptides, alongside omega-3 fatty acids designed to support cognitive function and mobility in geriatric animals.

Concurrently, the increasing crisis of pet obesity across the U.S. serves as a key driver for nutraceutical innovation. 56–59% of dogs and 58–61% of cats are overweight or obese, significantly elevating the risk for diabetes, cardiovascular complications, and severe musculoskeletal disorders. This epidemic has prompted American pet owners to aggressively seek proactive dietary strategies and functional supplements. Ingredients such as L-carnitine, specialized prebiotics, and metabolic modulators are increasingly incorporated into weight management protocols, often highly recommended by veterinary professionals to enhance satiety and support healthy weight reduction.

The U.S. market is further propelled by rapid advancements in microbiome science and the growth of digital-first distribution models. American research institutions and specialized diagnostic companies are pioneering affordable, DNA-based microbiome testing that allows for highly personalized, strain-specific probiotic supplementation. Simultaneously, the shift toward e-commerce, led by platforms like Amazon and Chewy, alongside direct-to-consumer subscription models, has revolutionized product accessibility. These digital channels not only bypass traditional retail markups but also facilitate the recurring revenue models that are essential for lifelong supplement regimens, firmly establishing nutraceuticals as a resilient, high-growth sector within the broader U.S. animal health industry.

Key Trends Driving the Pet Nutraceuticals Market

Dominance of Soft-Chew Formats and Compliance Engineering

A key trend shaping the U.S. pet nutraceuticals market is the growing consumer preference for soft-chew and chewable product formats. Historically, pet supplements were predominantly manufactured as hard tablets, capsules, or messy powders, which often resulted in severe administration challenges and poor compliance rates among pet owners. Today, soft-chews have captured 45–50% of the entire U.S. pet supplement market, completely revolutionizing how functional ingredients are delivered to companion animals.

This trend is mainly driven by the concept of compliance engineering. Manufacturers have recognized that the most efficacious supplement is useless if the animal refuses to consume it. By engineering nutraceuticals to perfectly mimic the texture, aroma, and palatability of high-value treats, often utilizing flavors like bacon, peanut butter, or smoked liver, companies have effectively eliminated the friction associated with daily dosing. Pet owners report 85%+ adherence rates with chewable formats vs. 45–55% with tablets, transforming what was once a stressful medical task into a positive bonding experience between owner and pet.

Leading U.S. brands, such as Zesty Paws and PetHonesty, have built huge, highly successful product portfolios almost exclusively around the soft-chew format. Zesty Paws alone generates $500M+ in annual revenue, while PetHonesty is the top-selling pet supplement brand on Amazon. Furthermore, this format is well-suited for the multi-ingredient, synergistic formulations that are currently dominating the market (70%+ of new launches are multi-ingredient soft-chews), allowing manufacturers to combine glucosamine, probiotics, and botanical extracts into a single, highly palatable delivery system. As companies continue to refine flavor-masking technologies to hide the bitter taste of certain active ingredients, soft-chews are projected to maintain their continued dominance over the U.S. market.

Segment Analysis

By Pet Type

Dogs

Dogs command the largest share of the U.S. pet nutraceuticals market, accounting for the majority of segment revenue. This dominance is propelled by high household penetration rates, escalating per-capita healthcare expenditure on canines, and the profound, deep-rooted humanization of dogs across American culture.

The United States boasts an extraordinary canine population, with estimates ranging from 73.3 million dogs (2024 APPMA data) residing in over half of all pet-owning households (58% of pet owners have dogs). Dogs typically generate substantially higher veterinary and nutritional spending than cats or other companion animals. This is largely due to the physical size of many dog breeds, which necessitates larger supplement dosages, and a higher cultural propensity among American owners to invest heavily in canine wellness, training, and preventive care.

Age-related and breed-specific health conditions serve as a primary driver for supplement demand in this segment. Large breeds, which are highly popular in the U.S., are highly predisposed to musculoskeletal disorders such as osteoarthritis and hip dysplasia (60–70% of senior large breeds have osteoarthritis). This sustains robust, continuous demand for premium joint support formulations containing glucosamine, chondroitin, and advanced collagen peptides.

Similarly, the rising awareness of canine cognitive dysfunction (14%+ of dogs 11+ years affected) and anxiety disorders, mainly separation anxiety in post-2020 (COVID-19 pandemic) environments, is driving the demand for specialized calming supplements and antioxidants (30%+ increase in anxiety supplement sales post-2020). As American pet owners increasingly prioritize extending the active years of their dogs, this segment is projected to remain the dominant revenue engine for the market.

Cats

The nutraceuticals market for cats is a rapidly growing segment of the U.S. pet nutraceuticals market. The growth of this market is primarily attributed to a shift in feline ownership demographics and a growing recognition of specific, preventive feline health requirements among American owners.

The U.S. feline population is huge, with estimates suggesting 94.2 million cats across the country (2024 APPMA data). Crucially, recent industry data indicates that kitten-owning households are reaching parity with puppy-owning households in millennial and urban demographics, signaling a significant surge in feline popularity, mainly among these demographics. Historically, American owners spent significantly less on feline healthcare compared to canines; however, the intense humanization trend is rapidly closing this spending gap. 

The demand for feline nutraceuticals is heavily concentrated on managing the unique physiological vulnerabilities of indoor cats. Urinary tract health remains a key concern (20–30% of cats develop urinary issues), driving strong demand for specialized cranberry extracts, L-methionine, and pH-modulating functional ingredients. Additionally, hairball control (fastest-growing cat nutraceutical category), digestive wellness, and stress management for multi-cat households are key growth areas. As the U.S. cat population continues to grow and owners become more educated about proactive feline wellness, this segment is anticipated to drive robust growth throughout the forecast period.

By Product Type

Proteins and Peptides

Proteins and Peptides hold the largest share of the U.S. pet nutraceuticals market in 2026. The substantial share of this segment is primarily driven by the high prevalence of musculoskeletal disorders in the aging American dog population and the extensive clinical validation supporting these specific bioactive compounds.

This segment heavily capitalizes on advanced bioactive collagen research, which has consistently demonstrated profound joint health benefits in veterinary clinical trials. As the U.S. pet population ages, osteoarthritis has emerged as a dominant, highly visible health concern that severely impacts an animal's quality of life. Collagen peptides, specifically engineered for high bioavailability in companion animals, provide essential building blocks for cartilage repair and joint fluid maintenance, offering a highly effective alternative or complement to traditional pharmaceutical pain management.

Beyond joint health, specialized proteins and bioactive peptides are increasingly utilized for immune system modulation, muscle retention in geriatric animals, and specialized hypoallergenic diets for pets with severe food sensitivities. The combination of high disease prevalence, lifelong supplementation requirements, and exceptionally strong veterinary recommendation rates ensures that proteins and peptides remain the absolute largest revenue-generating product segment in the U.S. market.

Probiotics and Prebiotics

Probiotics and Prebiotics are projected to grow at the fastest CAGR during the forecast period. The rapid growth of this market is primarily attributed to increasing advancements in the scientific comprehension of the companion animal microbiome and its critical role in digestion, immunity, nutrient utilization, and comprehensive systemic health.

Gastrointestinal disorders account for a significant portion of veterinary consultations in the U.S. This has increased demand for probiotics, prebiotics, postbiotics, and comprehensive gut-health formulations. The U.S. market is witnessing a surge in innovation, with specialized diagnostic companies developing affordable, DNA-based stool testing that allows veterinarians and owners to identify specific dysbiosis patterns and prescribe highly targeted probiotic strains, moving far beyond generic, broad-spectrum blends.

Furthermore, the growing understanding of the gut-brain axis has massively expanded the application of probiotics into behavioral management and cognitive support, areas of high concern for American pet owners. As veterinarians and consumers increasingly acknowledge the intrinsic, undeniable link between a healthy, balanced microbiome and overall animal vitality, probiotics and prebiotics are anticipated to remain the fastest-growing product category, commanding premium pricing and driving intense consumer loyalty.

Competitive Landscape

The U.S. pet nutraceuticals market is moderately fragmented, characterized by the presence of global pet care companies, animal health firms, specialized pet supplement manufacturers, and rapidly growing direct-to-consumer brands. Competition is driven by product efficacy, scientific validation, ingredient quality, brand recognition, veterinary recommendations, palatability, and distribution reach. The market continues to benefit from growing pet humanization, increasing preventive healthcare spending, and rising demand for functional products targeting joint health, digestive health, cognitive support, skin and coat health, and immune function.

Large multinational companies such as Mars, Incorporated (Royal Canin), Nestlé Purina PetCare Company, Hill's Pet Nutrition, Inc. (Colgate-Palmolive Company), Zoetis Inc., Elanco Animal Health Incorporated, Boehringer Ingelheim International GmbH, Virbac S.A., and Dechra Pharmaceuticals PLC maintain strong market positions through extensive research capabilities, veterinary relationships, broad product portfolios, and established distribution networks. At the same time, specialized supplement companies and emerging wellness-focused brands continue to gain traction through targeted formulations, premium ingredients, e-commerce expansion, subscription-based sales models, and consumer-focused marketing strategies.

Key Players in the U.S. Pet Nutraceuticals Market

• Mars, Incorporated (Royal Canin)
• Nestlé Purina PetCare Company
• Hill's Pet Nutrition, Inc. (Colgate-Palmolive Company)
• Zoetis Inc.
• Elanco Animal Health Incorporated
• Boehringer Ingelheim International GmbH
• Virbac S.A.
• Dechra Pharmaceuticals PLC
• Nutramax Laboratories, Inc.
• VetriScience Laboratories
• Zesty Paws (H&H Group)
• PetHonesty
• Native Pet
• PetIQ, Inc.
• Ark Naturals
• The Honest Kitchen